Hospital
Arh Tug Valley Health Services, INC.
Arh Tug Valley Health Services, INC. was paid $10.44M by Medicaid between Dec 2021 and Dec 2024, across 189 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoARH TUG VALLEY HEALTH SERVICES, INC.
PAINTSVILLE, KY 41240
PAINTSVILLE, KY 41240
33aNPI1437813441assigned 10/26/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.44M
24GClaims268,790
24DCodes billed189
24AFirst – last monthDec 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#30 of 36
Median peer was paid$36.08M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 187 | $0.00 | |
| 2022 | 93,342 | $2.91M | |
| 2023 | 92,765 | $3.61M | |
| 2024incomplete | 82,496 | $3.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 10,279 | 6,613 | $2.31M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10.0% | 10,771 | 7,476 | $1.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 4,368 | 1,914 | $966K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.6% | 3,309 | 2,496 | $791K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 4.1% | 1,446 | 336 | $427K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.6% | 6,745 | 2,810 | $375K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 2,467 | 1,691 | $295K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 3,765 | 2,455 | $283K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 3,848 | 1,943 | $252K |
| 71045 | Radiologic examination, chest; single view | 2.1% | 6,067 | 3,867 | $224K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.0% | 915 | 443 | $210K |
| 80053 | Comprehensive metabolic panel | 1.4% | 21,669 | 15,004 | $145K |
177 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 999 | $132K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 313 | $128K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 1,738 | $119K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.1% | 818 | $115K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 2,997 | $113K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 3,290 | $110K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 4,737 | $106K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,772 | $100K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,040 | $100K |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,039 | $98K |
| 71250 | <1% | 727 | $93K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 299 | $90K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,435 | $85K |
| 72131 | <1% | 710 | $83K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,636 | $82K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 264 | $79K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,669 | $78K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,111 | $77K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,765 | $77K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,481 | $70K |
| 80061 | Lipid panel | <1% | 6,155 | $69K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 837 | $51K |
| 72128 | <1% | 283 | $48K | |
| 82607 | <1% | 3,915 | $45K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,110 | $39K |
| 97161 | <1% | 573 | $35K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,390 | $34K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 557 | $34K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 737 | $33K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,036 | $30K |
| G0378 | Hospital observation service, per hour | <1% | 407 | $29K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 531 | $29K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,925 | $28K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 56 | $28K |
| 84484 | <1% | 4,307 | $27K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 328 | $26K |
| 72100 | <1% | 615 | $26K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 887 | $26K |
| 82652 | <1% | 809 | $25K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,453 | $22K |
| 83880 | <1% | 1,365 | $21K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,626 | $20K |
| 84681 | <1% | 1,308 | $20K | |
| 87040 | <1% | 2,679 | $15K | |
| 87631 | <1% | 123 | $15K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,325 | $15K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 39 | $15K |
| 73030 | <1% | 585 | $15K | |
| 82746 | <1% | 1,066 | $14K | |
| 73630 | <1% | 595 | $14K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 387 | $14K |
| 83735 | <1% | 3,992 | $13K | |
| 73610 | <1% | 461 | $11K | |
| 84403 | <1% | 576 | $11K | |
| 83525 | <1% | 1,310 | $11K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 576 | $11K |
| 84439 | <1% | 1,566 | $11K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 17 | $10K |
| 73130 | <1% | 399 | $9K | |
| 80074 | <1% | 213 | $8K | |
| 87070 | <1% | 1,712 | $8K | |
| 84550 | <1% | 2,360 | $8K | |
| 83690 | <1% | 2,948 | $8K | |
| 81001 | <1% | 5,396 | $7K | |
| 83605 | <1% | 1,743 | $7K | |
| 73562 | <1% | 227 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,430 | $6K |
| 82728 | <1% | 508 | $6K | |
| 86140 | <1% | 1,592 | $5K | |
| 83540 | <1% | 1,126 | $5K | |
| 83550 | <1% | 898 | $5K | |
| 82150 | <1% | 1,711 | $5K | |
| 80143 | <1% | 597 | $5K | |
| V2632 | Posterior chamber intraocular lens | <1% | 175 | $5K |
| 82803 | <1% | 562 | $5K | |
| 87186 | <1% | 1,042 | $4K | |
| 84703 | <1% | 1,479 | $4K | |
| 83527 | <1% | 392 | $4K | |
| 87077 | <1% | 1,343 | $4K | |
| 81025 | <1% | 1,511 | $4K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 328 | $4K |
| 93017 | <1% | 55 | $4K | |
| 95913 | <1% | 14 | $4K | |
| 82043 | <1% | 892 | $4K | |
| 73590 | <1% | 188 | $4K | |
| 86038 | <1% | 380 | $4K | |
| 84402 | <1% | 165 | $3K | |
| 87430 | <1% | 694 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 379 | $3K |
| 73090 | <1% | 182 | $3K | |
| 36600 | <1% | 665 | $3K | |
| 84270 | <1% | 165 | $3K | |
| 72110 | <1% | 71 | $3K | |
| 74022 | <1% | 52 | $3K | |
| 86200 | <1% | 273 | $3K | |
| 85610 | <1% | 1,775 | $3K | |
| 85730 | <1% | 1,522 | $3K | |
| 96376 | <1% | 378 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 764 | $3K |
| 82550 | <1% | 733 | $2K | |
| 97597 | <1% | 19 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 110 | $2K |
| 20610 | <1% | 17 | $2K | |
| 96367 | <1% | 50 | $2K | |
| 85651 | <1% | 721 | $2K | |
| 85378 | <1% | 620 | $2K | |
| 85652 | <1% | 865 | $2K | |
| 82570 | <1% | 373 | $2K | |
| 81003 | <1% | 2,287 | $2K | |
| 74018 | <1% | 42 | $2K | |
| 76536 | <1% | 17 | $2K | |
| 92523 | <1% | 13 | $1K | |
| 72072 | <1% | 25 | $1K | |
| 87075 | <1% | 420 | $1K | |
| 97035 | <1% | 110 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,469 | $1K |
| 84145 | <1% | 158 | $1K | |
| 87076 | <1% | 286 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 177 | $1K |
| 73110 | <1% | 61 | $1K | |
| 86431 | <1% | 267 | $1K | |
| 80299 | <1% | 155 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 139 | $1K |
| 96368 | <1% | 56 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 422 | $980.11 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 316 | $907.63 |
| 90715 | <1% | 74 | $895.81 | |
| 87807 | <1% | 225 | $867.42 | |
| 72040 | <1% | 27 | $841.00 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 97 | $810.27 |
| 85027 | <1% | 185 | $806.17 | |
| 86738 | <1% | 169 | $764.48 | |
| 84153 | <1% | 38 | $651.26 | |
| 93246 | <1% | 27 | $648.83 | |
| 93041 | <1% | 152 | $580.26 | |
| 93242 | <1% | 34 | $542.05 | |
| 87081 | <1% | 323 | $483.48 | |
| 95885 | <1% | 44 | $464.80 | |
| 84480 | <1% | 46 | $421.59 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 113 | $391.75 |
| 82962 | <1% | 418 | $372.09 | |
| 73120 | <1% | 12 | $371.82 | |
| 90714 | <1% | 50 | $343.33 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 116 | $333.87 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 536 | $323.67 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 194 | $279.29 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 236 | $278.22 |
| 82140 | <1% | 48 | $264.88 | |
| 73080 | <1% | 22 | $223.68 | |
| 80320 | <1% | 224 | $207.60 | |
| 12001 | <1% | 12 | $197.09 | |
| 94760 | <1% | 134 | $179.96 | |
| 86308 | <1% | 90 | $175.90 | |
| 80076 | <1% | 32 | $173.49 | |
| 80324 | <1% | 51 | $147.39 | |
| 84702 | <1% | 21 | $141.00 | |
| 84146 | <1% | 12 | $138.57 | |
| 86376 | <1% | 12 | $136.79 | |
| 83695 | <1% | 12 | $131.57 | |
| 84466 | <1% | 21 | $124.06 | |
| 94664 | <1% | 38 | $121.60 | |
| 84436 | <1% | 12 | $69.68 | |
| 80361 | <1% | 28 | $65.86 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 69 | $54.60 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 245 | $42.66 |
| 87420 | <1% | 14 | $41.73 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 60 | $40.77 |
| 84100 | <1% | 13 | $35.06 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 173 | $31.56 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 143 | $31.35 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 57 | $28.71 |
| 82009 | <1% | 13 | $22.01 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 13 | $11.48 |
| J3490 | Unclassified drugs | <1% | 92 | $6.84 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 195 | $0.01 |
| A9270 | Non-covered item or service | 0% | 569 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Parent organizationAPPALACHIAN REGIONAL HELATHCARE, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.